- Home
- QURE vs OGN Comparison
QURE vs OGN Comparison
Compare QURE & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QURE | OGN |
|---|---|---|
| Founded | 1998 | 1923 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | QURE | OGN |
|---|---|---|
| Price | $25.30 | $9.14 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 5 |
| Target Price | ★ $58.55 | $14.10 |
| AVG Volume (30 Days) | 1.7M | ★ 6.3M |
| Earning Date | 02-26-2026 | 02-12-2026 |
| Dividend Yield | N/A | ★ 0.82% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.91 |
| Revenue | $15,751,000.00 | ★ $6,301,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $142.93 | N/A |
| P/E Ratio | ★ N/A | $5.11 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.76 | $6.18 |
| 52 Week High | $71.50 | $17.23 |
Technical Indicators
Market Signals| Indicator | QURE | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 55.22 | 66.12 |
| Support Level | $21.64 | $8.17 |
| Resistance Level | $25.80 | $9.94 |
| Average True Range (ATR) | 1.74 | 0.45 |
| MACD | 0.47 | 0.14 |
| Stochastic Oscillator | 53.94 | 70.59 |
Price Performance
Historical ComparisonAbout QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
About OGN Organon & Co.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.